Anthrax News and Research

RSS
Anthrax is an acute infectious disease caused by the spore-forming bacterium Bacillus anthracis. Anthrax most commonly occurs in wild and domestic lower vertebrates (cattle, sheep, goats, camels, antelopes, and other herbivores), but it can also occur in humans when they are exposed to infected animals or tissue from infected animals.

Anthrax is most common in agricultural regions where it occurs in animals. These include South and Central America, Southern and Eastern Europe, Asia, Africa, the Caribbean, and the Middle East. When anthrax affects humans, it is usually due to an occupational exposure to infected animals or their products. Workers who are exposed to dead animals and animal products from other countries where anthrax is more common may become infected with B. anthracis (industrial anthrax). Anthrax outbreaks occur in the United States on an annual basis in livestock and wild game animals such as deer.

Anthrax infection can occur in three forms: cutaneous (skin), inhalation, and gastrointestinal. B. anthracis spores can live in the soil for many years, and humans can become infected with anthrax by handling products from infected animals or by inhaling anthrax spores from contaminated animal products. Anthrax can also be spread by eating undercooked meat from infected animals. It is rare to find infected animals in the United States.
BARDA cancels PharmAthene's RFP for Recombinant Protective Antigen Anthrax Vaccine

BARDA cancels PharmAthene's RFP for Recombinant Protective Antigen Anthrax Vaccine

New data from NanoBio's nanoemulsion-based adjuvant platform to be presented

New data from NanoBio's nanoemulsion-based adjuvant platform to be presented

PharmAthene presents Protexia clinical trial results at PHEMCE conference

PharmAthene presents Protexia clinical trial results at PHEMCE conference

PharmAthene's Valortim demonstrates potential for anthrax treatment

PharmAthene's Valortim demonstrates potential for anthrax treatment

New data from PharmAthene's anthrax vaccine program presented

New data from PharmAthene's anthrax vaccine program presented

Positive results from NanoBio's recombinant H5N1 flu antigen-nanoemulsion vaccine combination study

Positive results from NanoBio's recombinant H5N1 flu antigen-nanoemulsion vaccine combination study

PharmAthene to present its biological/ chemical weapons countermeasure program data at the HHS PHEMCE workshop

PharmAthene to present its biological/ chemical weapons countermeasure program data at the HHS PHEMCE workshop

Human Genome Sciences submits BLA for ZALBIN

Human Genome Sciences submits BLA for ZALBIN

Fourth-quarter and full year fiscal 2009 results announced by AVANIR Pharmaceuticals

Fourth-quarter and full year fiscal 2009 results announced by AVANIR Pharmaceuticals

Human Genome Sciences commences patient dosing in its HGS1029 inhibitor trial

Human Genome Sciences commences patient dosing in its HGS1029 inhibitor trial

First nationwide human immunology registry for infectious disease research

First nationwide human immunology registry for infectious disease research

Soligenix receives $9.4M NIAID grant to develop technology for advancing rapidly acting vaccines

Soligenix receives $9.4M NIAID grant to develop technology for advancing rapidly acting vaccines

Elsevier journal Vaccine releases a supplement dedicated to vaccines for biodefense

Elsevier journal Vaccine releases a supplement dedicated to vaccines for biodefense

Cigarettes are widely contaminated with bacteria, reveals study

Cigarettes are widely contaminated with bacteria, reveals study

Aradigm commences patient dosage in Phase 2 trial of novel inhaled ciprofloxacin formulation

Aradigm commences patient dosage in Phase 2 trial of novel inhaled ciprofloxacin formulation

FDA issues a Complete Response Letter for Human Genome Sciences' raxibacumab BLA

FDA issues a Complete Response Letter for Human Genome Sciences' raxibacumab BLA

Emergent BioSolutions acquires 55,000 square foot manufacturing facility from MdBio Foundation

Emergent BioSolutions acquires 55,000 square foot manufacturing facility from MdBio Foundation

Novel breakthrough may lead to new methods for sterilizing food and medical equipment

Novel breakthrough may lead to new methods for sterilizing food and medical equipment

Universal Detection Technology to showcase its bio-weapons detection technology at Milipol Paris 2009

Universal Detection Technology to showcase its bio-weapons detection technology at Milipol Paris 2009

UIC receives federal grant to develop new antibiotics against anthrax, tularemia and plague

UIC receives federal grant to develop new antibiotics against anthrax, tularemia and plague

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.